Biotech Values

[Bickema]

TEVA and APP Pharma Angiomax generic can enter the market in 2019

http://www.themedicinescompany.com/investors/sec-filing/7844757/aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTc4NDQ3NTcmRFNFUT0xJlNFUT0mU1FERVNDPVNFQ1RJT05fQk9EWSZleHA9JnN1YnNpZD01Nw%3D%3D

Under the License Agreement, the Company grants Teva a non-exclusive license under the Litigated Patents to sell a generic bivalirudin for injection product under a Teva ANDA (the “Teva Product”) in the United States beginning June 30, 2019 or earlier under certain conditions. Under the License Agreement, Teva will be required to pay the Company royalties on gross profits of its sales of the Teva Product under certain circumstances.

http://ir.themedicinescompany.com/mobile.view?c=122204&v=203&d=1&id=1651267

License by MDCO The settlement agreement includes a license by MDCO to APP and an affiliate of APP under which APP may launch a generic bivalirudin product in the U.S. on May 1, 2019. In certain limited circumstances, this license to APP could become effective prior to May 1, 2019 and could include an authorized generic bivalirudin product supplied by MDCO.

This a potential sale of the company may be whats preventing MDCO from signing a partnership with Eagle